Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 7/20 | 0.34 |
| ▸ | JAK1 | P23458 | 7/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346285 | 0.90 | TSHR (0.37) | TSHRALOX15USP2SMN1; SMN2CTSK | |
| SCHEMBL345672 | 0.84 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL346527 | 0.82 | MEN1 (0.35) | TSHRALOX15USP2SMN1; SMN2CTSK | |
| SCHEMBL345712 | 0.81 | JAK2 (0.42) | USP2SMN1; SMN2CTSKMEN1ALDH1A1 | |
| SCHEMBL21851983 | 0.78 | USP2 (0.44) | TSHRALOX15USP2SMN1; SMN2ALDH1A1 | |
| SCHEMBL1821374 | 0.75 | USP2 (0.42) | TSHRALOX15USP2SMN1; SMN2CTSK | |
| SCHEMBL345212 | 0.74 | USP2 (0.41) | TSHRALOX15USP2SMN1; SMN2ALDH1A1 | |
| SCHEMBL4278207 | 0.72 | USP2 (0.46) | TSHRALOX15USP2SMN1; SMN2ALDH1A1 | |
| SCHEMBL89886 | 0.71 | CTSK (0.40) | TSHRALOX15USP2SMN1; SMN2CTSK | |
| SCHEMBL31726620 | 0.71 | USP2 (0.45) | TSHRALOX15USP2SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716289-B2 | Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | TSHR 47/4885ALOX15 4451/4885USP2 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.